PEGylated Proteins Market Size, Share, By Type (Consumables, and Services), By Protein (Colony-stimulating factor, Interferons, Erythropoietin, Recombinant factor VII, and Other), By Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis,

PEGylated Proteins Market Size, Share, By Type (Consumables, and Services), By Protein (Colony-stimulating factor, Interferons, Erythropoietin, Recombinant factor VII, and Other), By Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder, and Others), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutes), and By Region - Trends, Analysis and Forecast till 2034

PEGylated Proteins Market is experiencing significant growth, driven by increasing demand for enhanced biologic drugs with improved stability, solubility and extended half-life. Advances in biotechnology, increasing incidence of chronic diseases and high approval of PEGylated drugs also support this market. However, high cost of goods and regulatory challenges may hinder market expansion.

PEGylated Proteins Market Report Highlights:

• In 2023, PEGylated Proteins market was estimated to be worth USD 1.34 Billion.
• By 2034, the target market is expected to grow to USD 5.67 Billion.
• Target market is expanding at a CAGR of 11.5%.
• North America held the largest share of the market in 2024.
• Asia Pacific is projected to be the fastest-growing market in the coming years.
• By protein type, the market is being dominated by the erythropoietin segment.
• On the basis of application, the cancer segment is leading the market.
• Based on end-user, the pharmaceutical & biotechnology companies segment is holding the dominant PEGylated proteins market share.

PEGylated Proteins Market Key Highlights:

• In August 2024, the EMA approved a new formulation of PEGylated interferon for the treatment of chronic Hepatitis C, under the name Approval of PEGylated Interferon for Hepatitis C. The new formulation is designed with improved pharmacokinetics, allowing it to be dosed bi-weekly instead of weekly, thus making the product more tolerable for the patient.

PEGylated Proteins Market Report Analysis:

Overview of Site-Specific PEGylation of Therapeutic Proteins:

A thiol-PEGylated antibody fragment of the anti-tumor necrosis factor (TNF)-α monoclonal antibody, certolizamab pegol, marketed as Cimzia, and an N-terminally PEGylated human recombinant granulocyte colony-stimulating factor (rh-GCSF), pegfilgrastin, marketed under the brand name Neulasta, are the two commercially available therapeutics where the PEG chain has been introduced in a site-specific manner.

Genetically encoding a single cysteine residue into a protein is one of the most used techniques for site-specific protein PEGylation. As cysteine makes up less than 1% of the overall amino acid composition of proteins and many cysteines are involved in disulphide linkages that render them insensitive to many thiol-specific reagents, this approach functions as a site-specific method for PEGylation. Reacting this free cysteine with a maleimide group affixed to a PEG moiety is the most frequent alteration.

Browse ∼50 market data tables and ∼45 figures through ∼191 slides and in-depth TOC on “PEGylated Proteins Market Size, Share, By Type (Consumables, and Services), By Protein (Colony-stimulating factor, Interferons, Erythropoietin, Recombinant factor VII, and Other), By Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder, and Others), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutes), and By Region - Trends, Analysis and Forecast till 2034”

PEGylated Proteins Market Competitive Landscape:

The major players operating in the market include Amgen Inc., Pfizer Inc., Merck Millipore, Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology USA, Inc., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd. Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Ltd.